Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) announced it will report its financial results for Q4 and the full year 2020 on February 11, 2021, at 4:30 p.m. ET. The company focuses on developing innovative therapeutics for neurotology, utilizing advanced drug delivery technology for sustained drug exposure. This technology addresses unmet medical needs such as Ménière’s disease, hearing loss, and tinnitus. Interested parties can access the live call by phone or via a webcast on the company's investor relations website.

Positive

• Focused on neurotology with a robust pipeline addressing unmet medical needs.
• Utilizes innovative drug delivery technology for sustained exposure.

Negative

• None.

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corporate update at 4:30 p.m. ET on February 11, 2021.

The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 3372182. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information, please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

When will Otonomy release its financial results?

Otonomy will release its financial results for Q4 and the full year 2020 on February 11, 2021, at 4:30 p.m. ET.

What is the focus area of Otonomy?

Otonomy is dedicated to developing innovative therapeutics for neurotology.

How can I access Otonomy's financial results call?

You can access the call by dialing (877) 305-6769 for domestic callers, or (678) 562-4239 for international callers, with conference ID 3372182.

What unmet medical needs does Otonomy address?

Otonomy addresses unmet medical needs including Ménière’s disease, hearing loss, and tinnitus.